tirzepatide clinical trial enrollment as Compared with Semaglutide for the Treatment of Obesity Tirzepatide versus Semaglutide Once Weekly
Description
Typical pricing: /month
How It Works Compounded Tirzepatide (GLP-1/GIP) is a once-weekly injectable therapy that mimics dual incretin hormones, potentially offering stronger support for appetite regulation and metabolic balance than GLP-1 alone
Appetite suppression is strong and weight loss is substantial
Egrifta, the brand-name form of Tesamorelin, is FDA-approved for HIV-associated lipodystrophy
When tirzepatide activates GLP-1 receptors, it stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central pathways in the hypothalamus
